# Purple Biotech LTD.: Form 20-F for the period ended Dec 31, 2024

- Company: [Purple Biotech LTD.](/companies/ppbt.md) (CIK 1614744)
- Form: 20-F
- Filed: 2025-03-10
- Accepted by EDGAR: Mar 10, 2025, 16:06 ET
- Period: 2024-12-31
- Accession: 0001213900-25-022192
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1614744/000121390025022192/ea0232483-20f_purple.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1614744/000121390025022192/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Net income | 12 months, 2024-01-01 to 2024-12-31 | −$7.2m | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months, 2024-01-01 to 2024-12-31 | $4.99 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2024-01-01 to 2024-12-31 | $4.44 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2024-01-01 to 2024-12-31 | −$14.4m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | at 2024-12-31 | $7.4m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2024-12-31 | $8.9m | ifrs-full:CurrentAssets |
| Total assets | at 2024-12-31 | $37.0m | ifrs-full:Assets |
| Current liabilities | at 2024-12-31 | $4.0m | ifrs-full:CurrentLiabilities |
| Shareholders' equity | at 2024-12-31 | $32.9m | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | at 2024-12-31 | 517,128,717 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1614744/000121390025022192/ea0232483-20f_purple.htm

Filed Mar 10, 2025.
Source: SEC EDGAR, the filing index for accession 0001213900-25-022192. Last ingested by Listed: Nov 6, 2026, 18:16 ET. No prices; not investment advice.